Tocqueville Asset Management L.P. Lowers Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Tocqueville Asset Management L.P. trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,755 shares of the company’s stock after selling 1,829 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Neurocrine Biosciences were worth $1,246,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in NBIX. Janus Henderson Group PLC raised its stake in shares of Neurocrine Biosciences by 6.1% during the second quarter. Janus Henderson Group PLC now owns 9,352,240 shares of the company’s stock worth $789,610,000 after acquiring an additional 540,279 shares in the last quarter. Advisor Group Inc. grew its holdings in shares of Neurocrine Biosciences by 17.8% in the second quarter. Advisor Group Inc. now owns 3,037 shares of the company’s stock worth $255,000 after purchasing an additional 459 shares during the last quarter. Aperio Group LLC grew its holdings in shares of Neurocrine Biosciences by 20.1% in the second quarter. Aperio Group LLC now owns 33,742 shares of the company’s stock worth $2,849,000 after purchasing an additional 5,642 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Neurocrine Biosciences by 18.0% in the second quarter. First Trust Advisors LP now owns 1,277,700 shares of the company’s stock worth $107,876,000 after purchasing an additional 194,643 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Neurocrine Biosciences by 174.0% in the second quarter. Fisher Asset Management LLC now owns 74,420 shares of the company’s stock worth $6,283,000 after purchasing an additional 47,257 shares during the last quarter. 96.15% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:NBIX opened at $94.38 on Thursday. The company has a market capitalization of $8.64 billion, a PE ratio of 429.00, a P/E/G ratio of 4.94 and a beta of 1.32. The firm has a fifty day moving average of $88.75. Neurocrine Biosciences, Inc. has a twelve month low of $64.72 and a twelve month high of $126.98. The company has a current ratio of 7.44, a quick ratio of 7.32 and a debt-to-equity ratio of 0.96.



Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Monday, July 29th. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.13. The business had revenue of $183.58 million for the quarter, compared to analysts’ expectations of $161.79 million. Neurocrine Biosciences had a net margin of 2.98% and a return on equity of 0.46%. The firm’s revenue for the quarter was up 89.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.07) earnings per share. Analysts predict that Neurocrine Biosciences, Inc. will post 0.8 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on NBIX. CIBC began coverage on shares of Neurocrine Biosciences in a report on Tuesday, July 16th. They issued an “outperform” rating and a $100.00 target price on the stock. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Oppenheimer began coverage on shares of Neurocrine Biosciences in a report on Tuesday, July 16th. They issued an “outperform” rating and a $100.00 target price on the stock. JPMorgan Chase & Co. upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $100.00 to $106.00 in a report on Monday, April 22nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. Neurocrine Biosciences presently has a consensus rating of “Buy” and a consensus target price of $107.15.

In related news, CEO Kevin Charles Gorman sold 80,000 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $95.31, for a total value of $7,624,800.00. Following the sale, the chief executive officer now owns 468,508 shares in the company, valued at $44,653,497.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gary A. Lyons sold 10,000 shares of Neurocrine Biosciences stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $92.07, for a total transaction of $920,700.00. Following the completion of the sale, the director now owns 235,697 shares in the company, valued at approximately $21,700,622.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 230,683 shares of company stock worth $21,039,998. 4.30% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.